<unk>  is indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Amivantamab
Glysobuzole
Glybuzole
Tirapazamine
Pivagabine
Valproate pivoxil
Influenzanet
Fosaprepitant